|
Thursday, April 27, 2023, San Antonio, Texas, 12:15 PM – 1:45 PM Central Time (1:15 PM – 2:45 PM Eastern Time)
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial ParticipationFifteenth Annual RTP Symposium Series Held During the Annual ONS CongressChronic Lymphocytic Leukemia
Location
Grand Hyatt San Antonio River Walk 600 E Market Street San Antonio, TX 78205 Hotel Phone: (210) 224-1234 Program Schedule — Central Time 11:45 AM – 12:15 PM — Registration 12:15 PM – 1:45 PM — Lunch Meeting Meeting Room Texas Ballroom (Salons A-C) – Fourth Floor This event will also be webcast live. Please see Registration tab for details. Faculty
John N Allan, MD Associate Professor of Clinical Medicine Weill Cornell Medicine New York, New York Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC Family Nurse Practitioner Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Corinne Hoffman, MS, APRN-CNP, AOCNP Nurse Practitioner, Hematology The James Comprehensive Cancer Center The Ohio State University Wexner Medical Center Columbus, Ohio Adam S Kittai, MD Assistant Professor Division of Hematology The Ohio State University The OSUCCC – James Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration 12:15 PM – 1:45 PM — Educational Lunch Meeting What I Tell My Patients About ... The Relevance of Biomarker Testing in Chronic Lymphocytic Leukemia (CLL)
First-Line Therapy for Newly Diagnosed CLL
The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL
Toxicities and Other Practical Considerations with BTK Inhibitors
The Tolerability and Duration of Venetoclax-Based Treatment
The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax
Available Therapies for R/R CLL and Promising Investigational Agents and Strategies
Target Audience
Accreditation Statement Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Allan — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc; Nonpromotional Disease State Awareness Speaking: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Broadway-Duren — Advisory Roles: AbbVie Inc, Pharmacyclics LLC, an AbbVie Company. Ms Hoffman — Advisory Board: BeiGene Ltd, Pharmacyclics LLC, an AbbVie Company. Dr Kittai — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Kite, A Gilead Company, Lilly; Consulting Agreement: AbbVie Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: BeiGene Ltd.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. Grand Hyatt San Antonio River Walk Meeting Room: The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:45 AM Central Time on Thursday, April 27th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com. Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability. LIVE WEBCAST registration open to all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|